Table 1.

Summary of demographic details, diagnostic criteria, immunohistochemistry, and brain areas studied in the different disorders

Disorder	N	Age	M:F	IHC	Diagnostic criteria	Regions studied
AD	6	78 (9.2)	3:3	AT8 (tau)	NINCDS/ADRDA/CERAD	SFG, SPL, ITG, PHG VC
PiD	10	65.3 (11.3)	7:3	TP70 (tau)	Cairns et al. (2007)	SFG, ITG, PHG
CBD	12	64.7 (9.07)	8:4	TP007 (tau)	NIH-ORD	SFG, SPL, ITG, PHG
PSP	8	73.4 (7.4)	4:4	TP70 (tau)	NINDS-SPSP	SFG, ITG, PHG
DLB	12	73.8 (7.2)	12:0	α116	CDLB (α-synuclein)	SFG, ITG, PHG
MSA	10	66.5 (8.51)	7:3	α116	MCC (α-synuclein)	SFG, ITG, PHG
NIFID	10	45.3 (12.1)	7:3	FUS	Cairns et al. (2007)	SFG, ITG, PHG
FTLD-TDP	15	69.6 (8.50)	7:2	TDP-43	Cairns et al. (2007)	SFG, ITG, PHG

AD Alzheimer’s disease, PiD Pick’s disease, CBD corticobasal degeneration, PSP progressive supranuclear palsy, DLB dementia with Lewy bodies, MSA multiple system atrophy, NIFID neuronal intermediate filament inclusion disease, FTLD-TDP frontotemporal lobar degeneration with TDP-43 proteinopathy, FUS fused in sarcoma, TDP-43 transactive response (TAR) DNA-binding protein, N number of cases studied, IHC immunohistochemistry, M male, F female, SFG superior frontal gyrus (B8), SPL superior parietal lobule (B7a/7b), ITG inferior temporal gyrus (B22), PHG parahippocampal gyrus (B28), VC visual cortex (B17). Diagnostic criteria: ‘National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association’ (NINCDS/ADRDA) (Tierney et al. 1988), ‘Consortium to Establish a Registry of Alzheimer Disease’ (CERAD) criteria (Mirra et al. 1991); National Institute of Health-Office of rare disorders (NIH-ORD); National Institute of Neurological Disorders and Stroke (NINDS) and the Society of PSP (SPSP) (NINDS-SPSP) (Hauw et al. 1994, Litvan et al. 1996); ‘Consortium on Dementia with Lewy bodies’ (CDLB)’ (McKeith et al. 1996); ‘Minneapolis Consensus Criteria (MCC) (Gilman et al. 1998); Diagnostic criteria for PiD, NIFID and FTLD-TDP according to Cairns et al. (2007)